Drug detox for Boynton Beach — substance-specific protocols, not one-size-fits-all.

RECO Island is a small-census, physician-led detox and residential facility seven miles south of Boynton Beach on Federal Highway — a 12-minute drive from Renaissance Commons or Ocean Ridge. Detox uses substance-specific protocols (COWS-guided buprenorphine induction for opioids, CIWA-guided tapering for alcohol and benzodiazepines, supportive management for stimulants) and transitions directly in-house to residential treatment with the same clinical team. No waitlists, no third-party handoffs, and in-person family involvement is logistically straightforward at this distance.

Boynton Beach sits seven miles north of RECO Island’s Delray Beach campus along Federal Highway — a 12-minute drive south that, for residents of Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, or Briny Breezes, is shorter than the trip to a typical Boynton supermarket. That matters clinically. Proximity means family sessions happen in person, a spouse can visit on a Saturday without rearranging the week, and discharge planning continues with the same clinical team rather than through a cold handoff. RECO Island is a small-census, physician-led medical detox and residential facility offering drug detox with substance-specific protocols and direct in-house transition to residential care — no waitlists, no third-party handoffs.

Substance-specific withdrawal protocols

Opioid, benzodiazepine, and stimulant withdrawal are clinically distinct syndromes. Managing them under one uniform protocol produces predictable failure — either undertreated withdrawal that drives against-medical-advice discharge, or overtreated withdrawal that adds iatrogenic risk. RECO Island runs a substance-specific approach, calibrated to the withdrawal syndrome the patient actually presents with rather than to a generic detox pathway.

Opioid withdrawal is intensely uncomfortable but rarely medically dangerous. Severity is scored with the Clinical Opiate Withdrawal Scale (COWS), and buprenorphine induction typically begins when the score crosses 8-12, converting an acute withdrawal experience into a manageable one within hours. For patients with contraindications, methadone induction is used. Benzodiazepine withdrawal carries the opposite risk profile — like alcohol, it can produce seizures, delirium, and autonomic instability. Management requires slow tapering, typically converting a short-acting agent to a long half-life equivalent (clonazepam or diazepam) and tapering over one to several weeks, with lorazepam for breakthrough symptoms.

Stimulant withdrawal from cocaine or methamphetamine has no specific medication protocol, but the clinical need is real — profound anhedonia, hypersomnia, dysphoria, and cravings peak in the first week. Supportive medical management, sleep restoration, nutritional rehabilitation, and psychiatric assessment for underlying mood disorders drive that phase. Where an unmasked depressive disorder emerges, sertraline or another SSRI is initiated during detox rather than deferred until an outpatient handoff many patients never complete.

Polysubstance detox and the sequencing decision

Concurrent alcohol, benzodiazepine, and opioid use — increasingly the presenting pattern rather than an exception — requires sequencing rather than parallel management. The governing principle is straightforward: manage life-threatening withdrawal first. Alcohol and benzodiazepines produce seizure risk and are addressed with CIWA-guided tapering for alcohol, or long half-life benzodiazepine conversion and taper. Opioid maintenance is initiated concurrently once the patient is stable enough for buprenorphine induction. Stimulant withdrawal is managed supportively alongside.

Every polysubstance admission is individualized against the actual use history — substances involved, quantities, duration, last-use timing, and prior withdrawal history including any prior seizures or DTs. The plan is documented before the first medication is administered, reviewed by the attending physician, and reassessed at each shift as the clinical picture evolves. Where the presenting use pattern includes fentanyl — now near-universal in the illicit opioid supply — buprenorphine induction is timed carefully to avoid precipitated withdrawal, occasionally using a low-dose (“micro-induction”) approach.

Medical comorbidity is the norm, not the exception

Years of chronic substance use produce medical consequences that predate the admission — hepatitis C from injection use, endocarditis risk, cardiovascular disease and cardiomyopathy from stimulant use, malnutrition, untreated chronic pain often self-medicated into the addiction, and undiagnosed hypertension, diabetes, or sleep apnea. For many patients, detox admission is the first meaningful medical contact in years. Deferring these findings to outpatient primary care after discharge is a common systems failure — one that RECO Island’s on-site medical evaluation is designed to close.

On-admission workup includes history and physical, CBC, comprehensive metabolic panel, hepatic function, hepatitis serologies, HIV screening, urine drug screen, and pregnancy testing where indicated. Psychiatric evaluation runs in parallel using structured instruments — PHQ-9 for depression, GAD-7 for anxiety, and ASRS where attentional symptoms are prominent. Findings are integrated into the active treatment plan rather than filed away. A patient who arrives with untreated hepatitis C leaves with linkage-to-care in place and, in the interim, hepatology-informed medication choices.

The handoff into residential and MAT continuation

Detox produces safe withdrawal. It does not produce recovery. The evidence on detox-only care is unambiguous — relapse rates in the weeks following an isolated detox episode approach universality. Detox is the first clinical step, not the intervention. RECO Island’s model is a direct in-house transition from detox into residential treatment on the same campus, with the same clinical team, no waitlist, and no repeat intake paperwork.

Medication for addiction treatment is initiated during detox where indicated and continued through residential and into PHP/IOP. For opioid use disorder, buprenorphine-naloxone is the standard, with extended-release naltrexone as an alternative after an appropriate opioid-free window. For alcohol use disorder, naltrexone or acamprosate is initiated. The residential curriculum layers evidence-based behavioral therapies onto that pharmacologic foundation — cognitive behavioral therapy (CBT) for craving management and relapse prevention, dialectical behavior therapy (DBT) skills for emotion regulation, motivational interviewing (MI) as the interpersonal frame, EMDR for trauma histories where indicated, and acceptance and commitment therapy (ACT) for values-based recovery.

At discharge, MAT continues through community prescribers with a warm handoff — not a prescription and a phone number. ASAM Criteria dimensions drive the discharge level-of-care decision, and for many Boynton Beach residents that means stepping down to PHP or IOP on the RECO Island campus, twelve minutes from home.

What to expect on admission day from Boynton Beach

Most admissions from Boynton Beach begin with a phone call to admissions, insurance verification completed in under an hour, and a same-day or next-day intake window. Transportation from a Boynton Beach residence is arranged when needed. On arrival, the patient is medically assessed within the first hour, withdrawal is scored (COWS for opioids, CIWA for alcohol), initial medications are administered per protocol, and the patient is oriented to the unit.

The first 24-72 hours are the acute withdrawal window. Vitals are monitored, symptom-triggered dosing is used where appropriate, and psychiatric evaluation is completed once the patient can sustain a coherent interview — typically within the first two to three days. Family contact is coordinated with written consent under 42 CFR Part 2; for Boynton Beach families, in-person family sessions during residential are logistically straightforward given the seven-mile distance.

Insurance and admissions from Boynton Beach

RECO Island works with the major commercial carriers relevant to Palm Beach County — Florida Blue, Blue Cross Blue Shield, Aetna, Cigna, UnitedHealthcare, and Humana. Benefits verification runs before intake, so the patient and family have concrete numbers on covered days, out-of-pocket exposure, and the authorized level of care before an admission decision is made. Level-of-care authorization is driven by ASAM Criteria dimensions rather than plan-fit convenience — and the entire pathway, from intake through step-down PHP or IOP, happens within a 12-minute drive of Boynton Beach.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.